triptolide has been researched along with Kaposi Sarcoma in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Guo, W; Long, C; Sun, X; Wang, H; Wang, J; Zhou, H | 1 |
| Bręborowicz, D; Bylka, W; Frankiewicz, D; Grzegorzewska, AE; Matławska, I | 1 |
2 other study(ies) available for triptolide and Kaposi Sarcoma
| Article | Year |
|---|---|
Triptolide decreases expression of latency-associated nuclear antigen 1 and reduces viral titers in Kaposi's sarcoma-associated and herpesvirus-related primary effusion lymphoma cells.
Topics: Animals; Antigens, Viral; Antineoplastic Agents, Alkylating; Cell Line, Tumor; Cell Proliferation; Cell Survival; Diterpenes; Down-Regulation; Epoxy Compounds; Gene Expression Regulation, Neoplastic; Gene Expression Regulation, Viral; Herpesvirus 8, Human; Humans; Lymphoma, Primary Effusion; Mice; Nuclear Proteins; Phenanthrenes; Sarcoma, Kaposi; STAT3 Transcription Factor; Viral Load; Xenograft Model Antitumor Assays | 2016 |
Disseminated cutaneous Kaposi sarcoma in a patient receiving triptolide/tripdiolide for rheumatoid arthritis.
Topics: Adult; Aged; Arthritis, Rheumatoid; Diterpenes; Edema; Epoxy Compounds; Female; Humans; Immunosuppressive Agents; Leg; Middle Aged; Phenanthrenes; Powders; Sarcoma, Kaposi; Skin Neoplasms | 2012 |